6533b81ffe1ef96bd1277043

RESEARCH PRODUCT

“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

Dimitri P. MikhailidisAlberto ZambonMatilda FlorentinBruce A. GriffinGiatgen A. SpinasWinfried MärzKlaus G. ParhoferEvangelos LiberopoulosVasilios G. AthyrosAlexandros D. TselepisRizzo ManfrediGerald H. TomkinMoses ElisafJacqueline De GraafKarl WinklerGiovam Battista RiniAnthony S. WierzbickiKaspar Berneis

subject

Pharmacologybusiness.industryStatement (logic)Bioinformaticschemistry.chemical_compoundFamilial combined hyperlipidemiachemistryLow-density lipoproteinImmunologyLow densityMedicineClinical significanceCardiology and Cardiovascular Medicinebusiness

description

Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

yearjournalcountryeditionlanguage
2011-09-01Current Vascular Pharmacology
https://doi.org/10.2174/157016111796642661